5th Annual Viral Safety and Viral Clearance Summit - Event Resources


October 6 – 7, 2020 | Virtual Event

5th Annual Viral Safety and Viral Clearance Summit - Event Resources logo

COVID-19 Immune Globulin Regulation

Dorothy Scott, MD
Branch Chief for the Laboratory of Plasma Derivatives, Office of Blood Research and Review, US FDA, Center for Biologics Evaluation and Research
 
Download PDF

 

SARS-CoV-2 Inactivation by Commonly Available Chemicals on Inanimate Surfaces

Eleonora Widmer, MD, PhD
Senior Director Global Pathogen Safety, CSL Behring
 
Download PDF

 

Decontamination of N95 Respirators in a Large Hospital System in the COVID-19 Emergency

Ebru Oral, PhD
Associate Professor of Orthopedic Surgery Harvard Medical School, Associate Director at Harris Orthopedic Lab at Massachusetts General Hospital, Fellow of the National Academy of Inventors


 

Developing and Implementing Viral Safety Strategies for Cell and Gene Therapy

David Hambly, PhD
President, Advanced Therapy Product Consulting, Inc.
 
Download PDF
 

 

Detection of Replication Competent Viruses in Viral Vector Products

Matthew Pennington, PhD
Scientist 1, Virology Department, Charles River
 
Download PDF
 

 

Testing for Replication Competent Viruses in Retroviral and Lentiviral Vector Products

Kenneth Cornetta, MD
Clinical Professor of Medical and Molecular Genetics, Indiana University School of Medicine Director, National Gene Vector Biorepository, Associate Director, Brown Center for Immunotherapy
 
Download PDF
 

 

Viral Safety in Continuous Manufacturing

Scott Lute, PhD
Biologist/Research Reviewer, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
 
Download PDF
 

 

Points to Consider for the Development of a Virus Inactivation Process

Jens-Peter Gregersen, DVM, PhD
Independent Biomedicines Consultant
 
Download PDF
 

 

Confronting Antigenic Diversity with Broad-Strain Vaccines

Christopher Locher, PhD
CEO, Versatope Therapeutics, Inc.
 
Download PDF
 

 

Current Perspectives on NGS for Adventitious Virus Detection

Arifa Khan, PhD
Senior Investigator in the Office of Vaccines Research and Review, U.S. Food and Drug Administration, Center for Biologics Evaluation and Research
 
Download PDF

 

Evaluation of RNA Next Generation Sequencing (Transcriptomics Analysis) to Replace In Vivo Tests for Assessing the Viral Safety of Cells

Horst Ruppach, PhD
Scientific and Portfolio Director, Global Biologics Charles River

Mark Eloit, DVM, PhD
Founder & Scientific Advisor, Pathoquest
 
Download PDF

 

Biotech Viral Safety: New Opportunities and Current Trends in Viral Clearance and Safety

 Kurt Brorson, PhD
 Vice President, Technical, Parexel
 
Download PDF
 

Decontamination of PPE via Vaporized Hydrogen Peroxide and Moist Heat Treatment

Cassidy Collins
Senior Technician, Process Evaluation, Charles River

 


 

 

Exploration of Production Conditions to Achieve High Titer Influenza A

Janalyn Frederick
Senior Technician, Process Evaluation, Charles River

Madison Gaiser
Technician 2, Process Evaluation, Charles River
 
 

 

 

Gene Therapy Studies (AAV Vector): Viral Clearance Challenges

Amanda Budzilowicz
Senior Technician, Process Evaluation, Charles River
 
 


 

 

Viral Clearance for Medical Devices (Case Study)

Crystal Reitman
Senior Technician, Process Evaluation, Charles River


 


 

 

Evaluating Effects of Pressure Fluctuations by Constant Flow Method on Viral Clearance

Esha Vyas
Field Applications Manager, Asahi Kasei Bioprocess America, Inc.